P21.07 Immune-Related Adverse Events with Durvalumab Consolidation in a Real-World Cohort of Patients with Non–Small Cell Lung Cancer (NSCLC)
- Resource Type
- Source
- Journal of Thoracic Oncology. 16:S366
- Subject
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Durvalumab business.industry non-small cell lung cancer (NSCLC) medicine.disease Immune system Internal medicine Cohort Medicine business Adverse effect - Language
- ISSN
- 1556-0864